<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992238</url>
  </required_header>
  <id_info>
    <org_study_id>R03155</org_study_id>
    <nct_id>NCT00992238</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the relative bioavailability of Flavoxate&#xD;
      Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas速&#xD;
      tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence according to US FDA guidelines</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Flavoxate Hydrochloride Tablets, 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Urispas速 Tablets, 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flavoxate Hydrochloride Tablets, 100mg</intervention_name>
    <arm_group_label>Flavoxate Hydrochloride Tablets, 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urispas速 Tablets, 100mg</intervention_name>
    <arm_group_label>Urispas速 Tablets, 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good health as determined by lack of clinically significant abnormalities in health&#xD;
             assessment performed at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive test results for HIV or Hepatitis B or C&#xD;
&#xD;
          -  History of allergy or sensitivity to Flavoxate hydrochloride or related drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flavoxate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

